Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A first-in-human Phase 1 clinical trial assessing LMNL6511

Next Previous
Trial Profile

A first-in-human Phase 1 clinical trial assessing LMNL6511

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 28 Sep 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs LMNL-6511 (Primary)
  • Indications Inflammation; Renal fibrosis
  • Focus Adverse reactions; First in man

Most Recent Events

  • 26 Sep 2023 According to Liminal BioSciences media release, the company expected to commence trial in the second half of 2023.
  • 09 May 2023 According to Liminal BioSciences media release, this trial will initiate the goal of identifying an early indicator of biological activity by the end of the clinical trial.
  • 15 Mar 2023 According to Liminal BioSciences media release, company plans to file for authorization to commence this trial in the second half of 2023.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top